SCHEMBL9893673

SCHEMBL9893673

CCOC(=O)c1nc(-c2ccc(C)cc2)n(-c2cc(Cl)ccc2C)c1-c1cccc(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 5/20 0.69
ALOX12 P18054 1/20 0.51
GABRA2 P47869 5/20 0.49
GABRB2 P47870 5/20 0.49
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
TRPM8 Q7Z2W7 1/20 0.45
HTT P42858 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP19A1 P11511 1/20 0.42
ELANE P08246 1/20 0.42
TARBP2 Q15633 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893837 0.94 MDM2 (0.77) MDM2ALOX12GABRA2GABRB2MAPT
SCHEMBL9893892 0.94 MDM2 (0.78) MDM2GABRA2GABRB2MAPTNPSR1
SCHEMBL9893895 0.93 MDM2 (0.67) MDM2ALOX12GABRA2GABRB2MAPT
SCHEMBL28799368 0.91 MDM2 (0.65) MDM2ALOX12GABRA2GABRB2MAPT
SCHEMBL28799394 0.91 MDM2 (0.70) MDM2ALOX12GABRA2GABRB2MAPT
SCHEMBL1437102 0.90 MDM2 (0.64) MDM2ALOX12GABRA2GABRB2MAPT
SCHEMBL9893991 0.88 MDM2 (0.64) MDM2ALOX12GABRA2GABRB2TRPM8
SCHEMBL9893841 0.88 MDM2 (0.66) MDM2ALOX12GABRA2GABRB2MAPT
SCHEMBL9893990 0.88 MDM2 (0.65) MDM2ALOX12GABRA2GABRB2MAPT
SCHEMBL1436973 0.87 MDM2 (0.89) MDM2ALOX12GABRA2GABRB2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885ALOX12 4534/4885GABRA2 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.